id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
work_dlnfqoqswzdmfacaxmi3dtua3i	Ajay K. Singh	Debate: PRO Position. Should Hemoglobin Targets for Anemic Patients with Chronic Kidney Disease Be Changed	2010.0	5	.pdf	application/pdf	3189	245	64	There is no evidence to indicate increased mortality or cardiovascular risk with other interventions in targeting a higher Hb – blood transfusions or iron. Several observational analyses [5–9] implicate exposure to high dosages of ESAs in explaining these adverse outcomes. The Normal Hematocrit study [1] enrolled symptomatic high-risk dialysis patients, who were randomized to the inability to achieve target hemoglobin and the requirement of high-dose epoetin were significantly associated with an increased hazard of the primary end point high hemoglobin arm from the primary trial was no longer significant (p = 0.49), while high-dose epoetin was associated with a 57% increased hazard to the primary end Thus, exposure to high doses of epoetin and not the targeted Hb independently predicted adverse outcomes in CHOIR. studied, patients administered higher doses of epoetin Higher epoetin doses were associated with increased of ESA in CKD patients is associated with increased risk.	./cache/work_dlnfqoqswzdmfacaxmi3dtua3i.pdf	./txt/work_dlnfqoqswzdmfacaxmi3dtua3i.txt